Fig. 1: Effects of pepinemab treatment on primary cognitive assessments in EM cohort B1. | Nature Medicine

Fig. 1: Effects of pepinemab treatment on primary cognitive assessments in EM cohort B1.

From: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Fig. 1

a,b, Observed mean changes from baseline (BL) by treatment group over time for the mITT sample of EM cohort B1. a, OTS measures time to a correct response (averaged over all trials per visit). b, PTAP measures tapping consistency as the reciprocal of the average standard deviation of inter-tap interval durations following cessation of aural cues (over all trials per visit). a,b, Error bars show one standard error on either side of the mean, with sample sizes at each time point for each group listed above the profile lines.

Back to article page